The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta‐Analysis
Objective Sodium glucose cotransporter 2 (SGLT2) inhibitors may induce urinary glucose excretion via the inhibition of renal glucose reabsorption, improve glycemic control, and lower body weight. The aim of this meta‐analysis was to evaluate weight changes in patients who received different dosages...
Gespeichert in:
Veröffentlicht in: | Obesity (Silver Spring, Md.) Md.), 2018-01, Vol.26 (1), p.70-80 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Objective
Sodium glucose cotransporter 2 (SGLT2) inhibitors may induce urinary glucose excretion via the inhibition of renal glucose reabsorption, improve glycemic control, and lower body weight. The aim of this meta‐analysis was to evaluate weight changes in patients who received different dosages of SGLT2 inhibitors.
Methods
Overall, 55 placebo‐controlled trials were included.
Results
The results indicated that treatment with 2.5 mg, 5 mg, 10 mg, and 20 mg of dapagliflozin led to significant decreases in body weight compared with a placebo (weighted mean difference [WMD], −1.30 kg, −1.51 kg, −1.79 kg, −2.24 kg, respectively; P |
---|---|
ISSN: | 1930-7381 1930-739X |
DOI: | 10.1002/oby.22066 |